This trial is active, not recruiting.

Condition endometrial cancer
Treatment lymphadenectomy
Phase phase 2
Sponsor Frederick R. Ueland, M.D.
Start date January 2012
End date September 2017
Trial size 200 participants
Trial identifier NCT01512810, 11-GYN-130-MCC


Complete pelvic and para-aortic lymphadenectomy performed at the time of primary surgical staging for endometrial cancer increases operative time and surgical morbidity, but appears to be necessary in most high grade and deeply invasive cancers. To date, the Mayo Clinic approach has not been reproduced, and the investigators propose to validate their algorithm at the University of Kentucky utilizing intra-operative consultation (IOC). The preliminary data at the University of Kentucky for IOC and endometrial cancer outcomes suggest that the investigators are well-suited to perform this investigation. A surgical approach that is tailored to the patient's cancer biology is rational, supported by the recent literature, and medically compelling since the co-morbidities of many obese, low-risk EC patients put them at significantly increased perioperative risk for complete lymphadenectomy.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(No Intervention)
No lymphadenectomy recommended
Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes

Primary Outcomes

Recurrence-free survival
time frame: 24 months

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - All patients must be surgical candidates for complete hysterectomy and bilateral salpingo-oophorectomy and pelvic and aortic lymphadenectomy. - Patients must have a histologically confirmed diagnosis of endometrial cancer and no clinical evidence of extra-uterine disease on preoperative evaluation. - Preoperative evaluation to rule-out extra-uterine disease may include CT scan, MRI, or ultrasound. Preoperative imaging is not mandatory for study enrollment. - Patients may have received prior systemic chemotherapy. Such therapy must have been completed at least 5 years prior to study entry and the patient has no evidence of disease subsequent to such therapy. Patients must not have received neoadjuvant chemotherapy for the present disease. - Patients must have GOG performance status 0, 1, or 2. - Patients must have an estimated survival greater than or equal to 3 months - Patients who have met the pre-entry requirements specified in Section 7.0. - Patients must have signed an approved informed consent and HIPAA authorization. Exclusion Criteria: - Patients with clinical evidence of disease beyond the uterus, including presence of suspicious aortic or inguinal nodes on imaging or clinical exam. - Patients who have received previous vaginal, pelvic, or abdominal irradiation. - Patients who received chemotherapy directed at the present disease. - Patients who have circumstances that will not permit completion of this study or the required follow-up. - Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of surgical lymph node assessments. - Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer within the last five years. - Patients with GOG Performance Grade of 3 or 4.

Additional Information

Official title Treatment of Endometrial Cancer Utilizing Pathology Intraoperative Consultation to Determine Extent of Surgical Staging
Principal investigator Frederick Ueland, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by University of Kentucky.